Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-09-06

FDA Approved: ORKAMBI — Supplemental Application (Vertex Pharmaceuticals Incorporated)

View source ↗

Summary

The FDA approved a supplemental application for Orkambi (lumacaftor and ivacaftor) submitted by Vertex Pharmaceuticals Incorporated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ORKAMBI (lumacaftor and ivacaftor)

Snippet

SUPPL AP for ORKAMBI (LUMACAFTOR AND IVACAFTOR)